In vivo activation of Treg cells with a CD28 superagonist prevents and ameliorates chronic destructive arthritis in mice.
Win, Stephanie J; Kühl, Anja A; Sparwasser, Tim; Hünig, Thomas; Kamradt, Thomas.
Eur J Immunol
; 46(5): 1193-202, 2016 05.
Artigo em Inglês | MEDLINE | ID: mdl-26711629
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28.
B Cells Drive Autoimmunity in Mice with CD28-Deficient Regulatory T Cells.
Natural regulatory T cells limit angiotensin II-induced aneurysm formation and rupture in mice.
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
T Cell Cosignaling Molecules in Transplantation.
In vitro polyclonal activation of conventional T cells with a CD28 superagonist protects mice from acute graft versus host disease.
CD28 superagonists: what makes the difference in humans?
Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28.
Protection from graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibody.